NCT02887976View on ClinicalTrials.gov

Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

PHASE3CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

October 6, 2017

Study Completion Date

October 6, 2017

Conditions
Prostate Cancer
Interventions
DRUG

SoluMatrix™ Abiraterone Acetate

SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor

DRUG

Methylprednisolone

Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate

Trial Locations (3)

67226

GU Research Network/Wichita Urology Group, Wichita

68130

GU Research Network/Urology Cancer Center, Omaha

68516

GU Research Network/Urology PC, Lincoln

Sponsors
All Listed Sponsors
collaborator

Churchill Pharmaceutical LLC

INDUSTRY

lead

GU Research Network, LLC

OTHER